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In this paper, we present whole-organ histologic and genetic mapping studies using hypervariable DNA
markers on chromosome 13 and then integrate the recombination- and single-nucleotide polymorphic sites
(SNPs)-based deletion maps with the annotated genome sequence. Using bladders resected from patients with
invasive urothelial carcinoma, we studied allelic patterns of 40 microsatellite markers mapping to all regions of
chromosome 13 and 79 SNPs located within the 13q14 region containing the RB1 gene. A whole-organ
histologic and genetic mapping strategy was used to identify the evolution of allelic losses on chromosome 13
during the progression of bladder neoplasia. Markers mapping to chromosomal regions involved in clonal
expansion of preneoplastic intraurothelial lesions were subsequently tested in 25 tumors and 21 voided urine
samples of patients with bladder cancer. Four clusters of allelic losses mapping to distinct regions of
chromosome 13 were identified. Markers mapping to the 13q14 region that is flanked by D13S263 and D13S276,
which contains the RB1 gene, showed allelic losses associated with early clonal expansion of intraurothelial
neoplasia. Such losses could be identified in approximately 32% bladder tumor tissue samples and 38% of
voided urines from patients with bladder cancer. The integration of distribution patterns of clonal allelic losses
revealed by the microsatellite markers with those obtained by genotyping of SNPs disclosed that the loss within
an approximately 4-Mb segment centered around RB1 may represent an incipient event in bladder neoplasia.
However, the inactivation of RB1 occurred later and was associated with the onset of severe dysplasia/
carcinoma in situ. Our studies provide evidence for the presence of critical alternative candidate genes
mapping to the 13q14 region that are involved in clonal expansion of neoplasia within the bladder antecedent to
the inactivation of the RB1 gene.
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Recent studies provide evidence that many common
epithelial cancers, including those arising in the
bladder, begin as clonal in situ expansion of
neoplastic cells, which show no or minimal devia-
tion from the normal phenotype.1–4 Such lesions
often form plaques involving large areas of the
affected mucosa and their expansion precedes the
development of microscopically recognizable dys-
plasia or carcinoma in situ.4,5 Identification of
chromosomal regions associated with the initial
expansion of neoplasia is a requisite for future
identification of their positional candidate genes
that may provide growth advantage for a neoplastic
clone.
Received 12 October 2005; revised 11 November 2005; accepted
12 November 2005; published online 9 January 2006
Correspondence: Dr B Czerniak, MD, PhD, Department of
Pathology, The University of Texas MD Anderson Cancer Center,
Box 085, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
E-mail: bczernia@mdanderson.org
*These authors contributed equally to this study
Laboratory Investigation (2006) 86, 175–190
& 2006 USCAP, Inc All rights reserved 0023-6837/06 $30.00
www.laboratoryinvestigation.org
We have previously reported the identification of
several chromosomal regions involved in early
clonal expansion of bladder neoplasia and con-
structed a genetic model of bladder cancer develop-
ment from occult intraurothelial precursor lesions.6–10
These studies utilized a whole-organ histologic
and genetic mapping approach with microsatellite
markers and low-resolution recombination-based
chromosomal maps. More recently, we have repor-
ted on whole-organ histologic and genetic mapping
of tumor suppressor gene loci using single-nucleo-
tide polymorphic sites (SNPs).11 These studies
provided evidence that a combined whole-organ
histologic and genetic mapping with SNPs can
provide valuable information on sequential hits in
early occult phases of human carcinogenesis.
Here, we report the results of our studies on
the evolution of losses on chromosome 13 in the
progression of bladder neoplasia from in situ
precursor conditions to invasive disease. Bladder
cancer was selected since it is a good human
tumor model for studies of early events in carcino-
genesis due to its simple anatomy and the ease in
mapping in situ neoplastic lesions across the entire
mucosa.12–14
In this paper, we present whole-organ histologic
and genetic mapping studies using hypervariable
DNA markers on chromosome 13 and then integrate
the recombination-based deletion maps with physi-
cal and genome sequence maps. Subsequently, the
high-resolution mapping of the RB1 region by
genotyping of SNPs is described. Finally, we present
the integration of allelic losses in 13q14 with RB1
sequencing, methylation status of its promoter, and
RB1 protein expression patterns in bladder mucosa.
Using this approach, it has been possible to identify
the pattern of RB1 involvement in the development
of bladder cancer and perhaps even more signifi-
cant provide evidence that genes near RB1 rather
than RB1 itself are involved in the initial in situ
expansion of a neoplastic clone.
Materials and methods
Tumor Tissues and Voided Urine Samples
Whole-organ histologic and genetic mapping of
chromosome 13 was performed on radical cystect-
omy specimens from eight patients (seven males and
one female) with untreated sporadic high-grade
(grade 3) invasive transitional cell carcinoma (TCC)
of the bladder. Their ages ranged from 47 to 82 years
(mean¼ 64.75713.1 s.d.). Subsequently, markers
mapping to deleted regions identified by whole-
organ mapping as well as their flanking markers
with retention of heterozygosity were tested on
DNA extracted from 25 frozen tumors and 21 voided
urine samples of patients with TCC. Urine samples
were collected before cystoscopy and the presence
of tumor was verified by pathologic examination
of intracystoscopically resected tumor tissue. The
precursor in situ lesions and tumor samples were
microscopically classified as described previously.5–10
In brief, the intraurothelial precancerous changes
were classified as mild, moderate, or severe dyspla-
sia or as carcinoma in situ. For the purpose of
statistical analyses, the intraurothelial precancerous
changes were classified into two major groups: low-
grade intraurothelial neoplasia (LGIN, mild and
moderate dysplasia) and high-grade intraurothelial
neoplasia (HGIN, severe dysplasia and carcinoma
in situ) as described previously.11 The TCCs were
classified according to the three-tier histologic
grading system of the World Health Organization
histologic grading system, and growth pattern
(papillary vs nonpapillary).15 The depth of invasion
was recorded according to TNM (tumor-node meta-
stasis) staging system.16 Stage T1 (lamina propria
invasion) has been divided into T1a (no muscularis
mucosae invasion) and T1b (muscularis mucosae
invasion), which have a clinically significantly
higher risk of progression.17 Consequently, the
tumors were dichotomized into superficial (Ta–T1a)
and invasive (T1b and higher) groups as described
previously.18 DNA was extracted from individual
bladder tumors and sediments of voided urine
samples as described previously.9 For controls,
DNA was also extracted from the peripheral blood
lymphocytes and/or normal nonbladder tissue in
the resected specimens from each patient.
Whole-Organ Histologic and Genetic Mapping
Whole-organ histologic and genetic mapping was
performed as described in our previous publica-
tions.6–10 In brief, each fresh cystectomy specimen
was opened longitudinally along the anterior wall
of the bladder and pinned down to a paraffin block.
The entire mucosa was divided into 1 2 cm
rectangular samples and evaluated microscopically
on frozen sections. The tissue of interest was
microdissected from the frozen block and cell
suspensions were prepared by mechanically scrap-
ing the urothelial mucosa or gently shaking invasive
tumor samples. Only those specimens that yielded
more than 90% of microscopically recognizable
intact urothelial, dysplastic, or tumor cells in each
sample were accepted for the study and used for
DNA extraction. This procedure provided 49, 39,
65, 42, 39, 30, 33, and 49 DNA samples from each of
the cystectomy specimens that corresponded to
microscopically identified intraurothelial precursor
conditions or invasive carcinoma.
In seven of the eight cystectomy specimens, a
single focus of grade 3 nonpapillary urothelial
carcinoma invaded the muscularis propria and was
accompanied by extensive precancerous lesions
ranging from mild dysplasia to carcinoma in situ.
In the remaining case, multiple foci of carcinoma
were present. One focus represented a grade 3
nonpapillary urothelial carcinoma with transmural
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invasion of the bladder wall and involvement of
perivesical adipose tissue. Two additional foci of
carcinoma represented grade 3 papillary urothelial
carcinoma without invasion. Like the other seven
cases, this case exhibited changes ranging from
mild dysplasia to carcinoma in situ over extensive
areas of the urinary bladder mucosa. The results of
microscopic evaluation of individual samples from
eight cystectomy specimens were recorded and
stored in a computer database as histologic maps.
Microsatellite Marker Analysis and Gene Candidate
Identification
The analysis of microsatellite markers and the
integration of recombination-based deletion map
of chromosome 13 with the physical maps and
the human genome sequence was performed as
described previously.9,10 In brief, a set of primers
for 40 microsatellite markers on chromosome 13
based on the sex-averaged microsatellite maps from
Genethon and Marshfield using reference families
from the Cooperative Human Linkage Center was
obtained from Research Genetics (Huntsville, AL,
USA; now Invitrogen, CA, USA). The allelic patterns
of markers were resolved on 6% polyacrylamide gels
after polymerase chain reaction (PCR) amplification.
A minimum 50% reduction in signal intensity was
required to be considered evidence of loss of
heterozygosity (LOH).
During the course of this study, the mapping,
genome sequence, and annotation resources avail-
able underwent a rapid evolution. An elaborate
integration strategy was necessary to move from the
genetic recombination-based microsatellite map to
the genome sequence. These efforts can now be
accomplished by finding the marker coordinates
on the latest build of the human genome available
via either the UCSC Genome Browser or Ensembl
genome browser (http://genome.ucsc.edu/ or http://
www.ensembl.org, respectively) and then using the
Vertebrate Genome Annotation browser (http://
vega.sanger.ac.uk/) to scan the region for genes and
gene predictions.
Genotyping with SNPs
Whole-organ genotype with SNPs was performed as
described previously.10 In brief, the positions of all
currently defined SNPs mapping within the 13q14
region from the SNP database of NCBI (http://
www.ncbi.nlm.nih.gov/SNP) were integrated with
the genome sequence map containing genes and
gene predictions. The integrated gene and SNP map
of the region was used to select 79 SNPs mapping
within the approximately 800 kb segment around
RB1, which included 30 SNPs located within the RB
gene. The genotyping of SNPs was performed by
pyrosequencing methods.19,20 For pyrosequencing,
genomic DNA fragments containing SNPs were
amplified by PCR with one of each primer biotiny-
lated at the 50-end. Single, stranded DNA was
isolated by streptavidin-coated magnetic beads
(Dynabeads M-280, Dynal, Oslo, Norway). The
sequencing reaction mixture contained the single-
stranded DNA with sequencing primer annealed,
DNA polymerase, apyrase, luciferase, ATP sulfury-
lase, adenosine 50-phosphosulfate, and luciferin.
Genotyping of SNPs was performed using an
automatic pyrosequencing instrument PSQt 96
MA (Pyrosequencing AB, Uppsala, Sweden). The
sequence was determined from the measured signal
output of light upon nucleotide incorporation. The
resulting peaks were analyzed using pyrosequen-
cing software. A minimum of 50% of signal
intensity reduction from one of the polymorphic
nucleotides was used to identify allelic loss.
Genotyping of SNPs was performed in three sequen-
tial steps. Initially, all selected SNPs of normal
genomic DNA were sequenced. In the next steps,
those SNPs that exhibited polymorphism were
tested on paired normal-invasive tumor DNA sam-
ples of the same patient. In the final step, those
SNPs that showed allelic loss were tested on all
mucosal samples of the same cystectomy specimen.
The distribution of clonal allelic losses of each SNP
were subsequently superimposed over the histologic
map of the entire organ and integrated with the
distribution patterns of clonal allelic losses identi-
fied by the hypervariable DNA markers.
Sequencing of RB1 Gene
The 27 exons of RB1 were amplified and directly
sequenced by applying the Taq cycle sequencing dye
terminator protocol. PCR products were purified
from unincorporated primers and dNTPs by using
exonuclease I and shrimp alkaline phosphatase.
Sequencing reactions were analyzed with an ABI
3730 sequencer (Applied Biosystems, Foster City,
CA, USA). Sequencing was repeated with primers
of reverse direction. Initially, all 27 exons of RB1
were sequenced on representative DNA samples
corresponding to invasive TCC of each cystectomy.
Subsequently, those exons, which showed muta-
tions, were sequenced on all mucosal samples of the
same cystectomy, and the distribution patterns of
the mutations were superimposed over histologic
maps of their cystectomy specimens.
Immunohistochemical Analysis of RB1 Protein
Expression
RB1 protein status was determined by immuno-
histochemical analysis of frozen sections using the
RB-WL-1 polyclonal anti-RB antibody as described
previously.21–23 RB-WL-1 is a rabbit polyclonal
antibody produced against a peptide encoded
by exon 10 of RB1. In Western blot analyses,
this antibody recognizes both phosphorylated and
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underphosphorylated forms of the RB1 protein.
Staining can be completely blocked by an excess of
the immunizing peptide. For immunohistochemical
staining, frozen sections stored at 701C were
defrosted for 30 min at room temperature and fixed
in cold methanol:acetone (1:1 volume) at 41C for
10 min. After being rinsed three times in PBS, they
were incubated for 15 min with 0.1% H2O2 in PBS,
followed by 15 min incubation with avidin-blocking
solution and 15 min incubation with biotin-blocking
solution (Vector Laboratories Inc., Burlingame,
CA, USA). The sections were then blocked with
10% goat serum in 2% BSA–PBS for 30 min and
incubated overnight at 41C with RB-WL-1 polyclonal
anti-RB1 antibody at 0.25 mg/ml in 2% BSA–PBS.
The bound antibody was visualized by avidin–
biotin complex assay using a VECTASTAIN ABC
Kit (Vector Laboratories Inc., Burlingame, CA, USA)
with 3,30-diaminobenzidine as a chromogen. The
sections were washed, counterstained with hema-
toxylin, dehydrated, and mounted. The immuno-
histochemical staining for RB1 protein was performed
on all mucosal samples of the eight cystectomies and
on additional 14 bladder tumor samples. HGIN and
TCC lesions were considered to be RB1 negative
only if the cells showed no RB1 nuclear staining and
contiguous RB1-positive normal cells were present
as an internal positive control. Sections of human
TCC with a known sequence status (wild type
and mutant) of RB1 were included as positive and
negative controls in each run. Additional negative
controls consisted of sections in which the positive
nuclear stain with RB-WL-1 antibody was blocked
by an excess of the immunizing peptide. To rule out
nonspecific binding of the detection system compo-
nents, sections with known positive staining for
RB1 gene were processed without incubation with
RB-WL-1. The RB1 protein status was finally super-
imposed over the histologic map and compared with
the distribution patterns of RB1 sequencing data as
well as losses within the 13q14 region.
Methylation-Specific PCR for RB1 promoter region
To rule out the possibility of loss of RB1 protein
expression due to methylation of the RB1 CpG
island, a methylation-specific PCR (MPS) was
performed on DNA corresponding to invasive TCC
from eight cystectomy specimens. The methylation-
specific PCR for RB1 CpG island was designed and
carried out as described previously.24,25 Briefly, 1 mg
of DNA was denatured by incubation with 0.2 M
NaOH for 15 min at 371C. Aliquots of 10 mM
hydroquinone (30 ml) (Sigma Chemical Co., St Louis,
MO, USA) and 3 M sodium bisulfite (pH 5.0, 520 ml)
(Sigma Chemical Co.) were added, and the solution
was incubated at 521C for 16 h. Treated DNA was
purified by use of a Wizard DNA Purification
System (Promega Corp., Madison, WI, USA). Modi-
fied DNA was stored at 801C until used. Treatment
of genomic DNA with sodium bisulfite-converts
unmethylated cytosines (but not methylated cyto-
sines) to uracil, which are then converted to
thymidine during subsequent PCR.24 Thus, after
bisulfite treatment, alleles that were originally
methylated have DNA sequences different from
those of their corresponding unmethylated alleles,
and these differences can be used to design PCR
primers that are specific for methylated or unmethy-
lated alleles. Unmethylated primers for p16 were
Figure 1 Assembly of whole-organ histologic and genetic maps. (a) A gross photograph of an open cystectomy specimen with an invasive
carcinoma (an area indicated by a white line) (upper panel) (map 5). The histologic map of the entire organ was generated by dividing the
mucosa into 12 cm rectangular samples, which were evaluated microscopically on frozen sections stained with hematoxylin and eosin.
The results of microscopic evaluation of individual samples were recorded as a histologic map (lower panel). The histologic map code is
as follows: NU, normal urothelium; MD, mild dysplasia; MdD, moderate dysplasia; SD, severe dysplasia; CIS, carcinoma in situ; and
TCC, invasive transitional cell carcinoma. An example of the relationship between allelic loss for three markers (RB1.2, RB1.20, and
D13S268) and the development of precancerous in situ conditions is shown. The positions of these markers on the sex-averaged
recombination-based map of chromosome 13 as well as their band positions are shown on the left. The areas that were involved by clonal
allelic losses of markers were superimposed over the histologic map and are delineated by continuous, interrupted, and dotted lines. The
markers RB1.2, RB1.20, and D13S268 show overlapping plaque-like clonal LOH involving almost the entire mucosa. (b) Representative
microscopic samples of NU, precursor in situ conditions, preneoplastic lesions, and TCC are shown. For the statistical analysis,
intraurothelial precursor conditions were classified into two groups: low-grade intraurothelial neoplasia (LGIN, mild to moderate
dysplasia) and high-grade intraurothelial neoplasia (HGIN, severe dysplasia and carcinoma in situ). (c) Examples of clonal LOH
involving almost the entire bladder mucosa for the marker RB1.20 located within intron 20 of RB1 and marker D13S268 located
approximately 3 Mb telomerically from RB1 in the same cystectomy specimen as shown in (a) are illustrated (map 5). In addition, a
marker D13S268 with retention of heterozygosity in all mucosal samples from map 4 is shown. Finally, marker D13S217 with LOH
involving the smaller allele in areas of bladder mucosa corresponding to HGIN and TCC from map 5 is shown. Sample #1 shows the
allelic pattern of the marker from peripheral blood lymphocytes (PBDNA) from the same patient and is used as a control. The presence of
allelic imbalance indicative of LOH was confirmed by densitometry and is provided as the OD ratio below each sample. ODr0.5 was
considered indicative of LOH. (d–f) Examples of allelic losses based on testing of all 40 markers on chromosome 13 identified in map 4
(d), map 5 (e), and map 6 (f) are shown. The vertical axes represent recombination-based maps of chromosome 13 with positions of
markers and their chromosomal locations. Only markers with allelic loss are shown. The shaded blocks represent areas of urinary
bladder mucosa with LOH as they relate to progression of neoplasia as shown in a histologic map of cystectomy depicted at the bottom of
each diagram. Note that several markers show clonal LOH in the form of plaques involving large areas of urinary bladder mucosa.
Although each specimen shows a distinct pattern of losses, markers mapping to 13q14 region that contain RB1 consistently exhibited
clonal allelic losses in the form of overlapping plaques involving large areas of bladder mucosa. Such a pattern of losses indicates that
they were involved in early incipient phases of bladder neoplasia associated with clonal in situ expansion antecedent to the development
of microscopically recognizable precursor conditions such as dysplasia. More important markers mapping to flanking regions of RB1
were at times asynchronous with losses of markers located within RB1 (see map 4 shown in (d).
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used to confirm the integrity of tissue-extracted
bisulfite treated DNA.25 DNA from peripheral blood
lymphocytes of healthy volunteers were used as
negative controls for MSP assays. The DNA samples
from peripheral blood lymphocytes treated with SssI
methyltransferase (New England Biolabs, Beverly,
MA, USA) and subjected to bisulfite treatment was
used as a positive control for methylated alleles.
Water blanks and PCR cocktails (without template)
were used as negative controls in each assay. PCR
products were visualized on 2% agarose gels stained
with ethidium bromide.
Analysis of Data
The patterns of allelic losses identified by the
microsatellite SNP markers and their relationship
to the development of bladder neoplasia were ana-
lyzed by nearest-neighbor and binomial maximum-
likelihood algorithms as described previously.6–11
For statistical analyses, the whole-organ histologic
and genetic mapping data were organized in a 2 4
contingency tables (fji, j¼ 1, 2; i¼ 1,y, 4). The
columns designated whether the marker retained
or lost heterozygosity and the four grades repre-
sented the microscopic status of the urothelium
(D0 normal urothelium (NU), D1 low-grade intra-
urothelial neoplasia, D2 high-grade intraurothelial
neoplasia, and D3, TCC).
A nearest-neighbor analysis was performed on the
three-dimensional stacks of maps consisting of plots
of marker alterations by location on the histologic
bladder maps and on chromosomal vectors. An
altered region was considered a neighbor of another
altered region if the two were side by side in the
same marker plot above and below each other. An
altered region was also considered to be connected
to another altered region if there was a continuous
string of altered regions between them. Since the
bladder was laid open and pinned flat, the left- and
right-most regions were also neighbors.
The binomial maximum-likelihood analysis was
performed in the same 2 4 contingency tables. The
maximum likelihood of the binomial distribution
was calculated for each urothelial status (Di, i¼ 0,y,
3) corresponding to NU, LGIN, HGIN, and TCC. The
maximum likelihood for the binomial distribution
was used to determine whether a row of data was
consistent with a hypothesis of an unchanged (all
negative) marker by calculating the log likelihood
with
li ¼ ln y
f1i
i ð1  yiÞf2i
y^f1ii ð1  y^iÞf2i
 !
Figure 2 Deletion map of chromosome 13 assembled from data
generated by whole-organ histologic and genetic mapping. A list
of all tested markers and their positions according to the updated
Cooperative Human Linkage Center Map is shown. Chromosomal
band locations are provided for markers with LOH only. Markers
printed in red showed statistically significant relationship
between LOH and the development of urothelial neoplasia tested
by binomial maximum-likelihood analyses and calculated as LOD
scores. Red bars on the left side of the map identify the deleted
regions, which are defined by the positions of deleted markers
and their nearest flanking markers with retention of heterozygo-
sity and the predicted size of the deleted regions in centimorgans
(cM, centimorgans; WOHGM, whole-organ histologic and genetic
mapping of individual cystectomy specimens consecutively
numbered 1–8. J, markers with retention of heterozygosity; K,
markers with LOH, and Ø, noninformative marker).
Figure 3 Summary of physical map and sequence database analysis spanning the deleted regions of chromosome 13. The Genethon
positions of the markers defining the deleted regions were related to the GB4 radiation hybrid panel-based physical map. The new
positions for the Genethon markers with LOH as well as flanking markers on the GB4 map were identified by electronic PCR search of
BAC contigs. In addition, multiple alternative markers based on their proximity to markers with LOH were identified and added to the
map. The nearest substitute markers are often located within the same BAC clone as original Genethon markers used for LOH studies.
Consequently, some of the original Genethon and substitute markers have the same position on the GB4 map. The original Genethon
markers with LOH are shown in red, while all other substitute and flanking markers are printed in black. An average EST density is
provided for regions flanked by individual markers using the GB4 radiation panel map. The list of known genes within the target regions
and their positions on the GB4 map is shown. In the final steps, we extracted all known, proposed, and predicted genes between markers
using the sequence-based mapping tools at the Ensemble website and the ‘Golden Path’ Genome Browser and constructed final sequence-
based map of the deleted chromosomal regions putatively involved in progression of bladder neoplasia from precursor conditions to
invasive cancer. To simplify the diagram, only the first position of a gene sequence on the GB4 map is shown. More complete data with
contigs information and alternative positions of the genes as well as the addresses for gene sequences can be obtained from http://
www.mdanderson.org/BladderGenomicMaps.
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for the null hypothesis H0, where y¼ yi and y¼ f1i/
(f1iþ f2i) is the maximum-likelihood estimate of a
negative marker. Two times the negative of the log
likelihood, 2li, is asymptotically w2 with 1 df, w2(1).
This expression can be written as
2li ¼2 lnð10Þ log10
y^f1ii ð1  y^iÞf2i
yf1ii ð1  yiÞf2i
 !
¼2 lnð10ÞLODðy^i : yiÞ
where LOD(y^i:yi) is the LOD-score function evalu-
ated at yi.26 Each row of the table for which 2li have
approximate w2(1) can be tested separately (strin-
gency level 1) or all rows for diagnosis Di
and more advanced (Di ,y, D3) can be combined
(stringency level 2) to get
f1iþ ¼
X3
j¼i
f1j
f2iþ ¼
X3
j¼i
f2j
LODðy^iþ : yiþÞ ¼ log10
y^f1iþiþ ð1  y^iþÞf2iþ
yf1iþi ð1  yiþÞf2iþ
 !
;
which is also w2(1) after adjustment by 2 ln(10)¼
4.605. As the maximum-likelihood estimates for
the individual rows are usually different from each
other, the sum of the LOD scores and the sum of the
w2 were greater than the combined statistics.
A w2 test for heterogeneity was appropriate to test
the combined estimate.26 Usually, yi¼ 0.5 is used to
test linkage in familial disorders with meiotic
segregation of the phenotype.27 With reference to
sporadic cancer and especially when populations
of tested cells represent sequential stages of the
process with mitotic transmission of the phenotype,
the null hypothesis is more appropriately verified at
y differing from 0.5. For example, a value of 0.99 is
more appropriate if the marker is unchanged in the
tissue, and a value of 0.01 is more appropriate for
determining whether the marker has been altered
from an unchanged to a changed state in the later
stages of the process, that is, invasive carcinoma.
The pattern of LOD scoresZ3 at y¼ 0.01 or 0.99 and
LOD scores o3 at y¼ 0.5 for the same marker is
significant. The strongest association between an
altered marker and neoplasia is when an LOD score
isZ3 at y¼ 0.99 and 0.5 ando3 at y¼ 0.01. It has to
be understood that the use of LOD in linkage
analysis of familial genetic predisposition for dis-
eases is intended to be used in its generic mathe-
matical sense as likelihood tests of events. We used
the LOD score variant of the likelihood test as many
researchers are more familiar with approximate
levels of significance when expressed in this form.
The analysis of the relationship among LOH in
individual loci and various clinicopathological
parameters of tumors and of voided urine samples
was tested by Gehan’s generalized Wilcoxon and
log-rank tests (Pr0.05 was considered significant).
Results
Recombination-Based Deletion Map of
Chromosome 13
We searched for allelic losses using the 40 hyper-
variable DNA markers mapping to chromosome 13.
Our initial analysis of paired normal and tumor
DNA samples identified LOH in five of eight
cystectomy specimens and they involved 14 of 40
tested markers. Markers with LOH were subse-
quently tested on all mucosal samples, and their
losses were related to the geographic distribution
of intraurothelial neoplastic lesions and invasive
cancer (Figure 1a–f). Four clusters of allelic losses
mapped to distinct regions of chromosome 13 were
identified (Figure 2). The deleted regions defined
by the nearest flanking markers with retention of
heterozygosity and their predicted size in centi-
morgan (cM) were as follows: 13q12 (D13S175–
D13S289, 16.9cM), 13q13 (D13S260–D13S267, 3.2cM),
13q14 (D13S263–D13S276, 17.0cM), 13q31 (D13S170–
D13S159, 16.0 cM).
The segment flanked by D13S263 and D13S276,
which contains RB1, showed clonal allelic losses in
five of eight tested bladders. Clonal allelic losses in
this region involved large areas of bladder mucosa
encompassing not only invasive cancer and adjacent
severe dysplasia or carcinoma in situ but also
areas of low to moderate dysplasia focally extending
to areas of microscopically NU. Clonal losses of
individual markers mapping to this region formed
closely overlapping plaques over a large area of
bladder mucosa, suggesting that such losses are
associated with the in situ expansion and establish-
ment of a dominant preneoplastic clone (Figure 1a–f).
More importantly, losses of markers located around
Figure 4 Summary of data on allelic losses using markers mapping to deleted regions of chromosome 13 tested in 25 bladder tumors and
21 voided urine samples. (a) A list of alterations in individual bladder tumor tissues and voided urine samples is provided. The losses are
related to clinicopathologic parameters such as growth pattern, histologic grade, and stage of tumor. Markers located within RB1 are
designated by a shaded area. Markers mapping to centromeric (Cent) and telomeric (Tel) regions flanking RB1 are designated by the
brackets at the bottom of the figure. The immunohistochemical results of RB protein expression (RB1(IH)) in 14 tumor samples are
summarized in the boxed column on the right. The bladder tumor and voided urine samples listed are not from the same patients. (b)
Frequency of allelic loss in four deleted regions on chromosome 13 is shown. Loss in the 13q14 RB1-containing region can be detected in
32 and 38% of bladder tumors and voided urine samples, respectively. (c) Frequency of allelic loss in centromeric-(Cent) and telomeric-
(Tel) flanking regions and within RB1 is illustrated.
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RB1 were at times asynchronous with a loss of
markers located within RB1 (Figure 1d–f). The
allelic losses of the three remaining segments
mapping to 13q12, 13q13, and 13q31 exhibited a
limited relationship to clonal expansion of intra-
urothelial neoplastic lesions, suggesting they do not
necessarily progress to invasive carcinoma.
Integration of Recombination-Based Deletion Map
with Genome Sequence Database
The deleted regions of chromosome 13 defined by
hypervariable DNA markers were integrated with
the physical map and ultimately with the human
genome sequence (Figure 3). Using this approach,
we were able to identify all known and predicted
genes mapping to the regions involved in bladder
neoplasia. Besides the model tumor suppressor
gene, RB1, 29 known and 71 predicted genes, some
of which were putative tumor suppressor genes,
were identified in the most frequently deleted
region mapping to 13q14. Other less frequently
deleted regions of chromosome 13 also contained
genes with well-established tumor suppressor func-
tions such as BRCA2, which maps to 13q13 region.
In addition, all deleted regions on chromosome 13
involved in bladder neoplasia contained several
genes involved in cell cycle regulation or coded for
proteins regulating cell differentiation and cell–
stroma interactions.
Testing of Tumors and Urine Samples
Since the major limitation of whole-organ histologic
and genetic mapping studies is that they can only
be performed on a limited number of cases, we
have tested the markers located within the dele-
ted regions on chromosome 13 on a larger number
of tumor and voided urine samples from patients
with bladder cancer (Figure 4a). This approach
revealed that allelic loss of markers mapping to
the 13q14 RB1-containing segment could be detec-
ted in approximately 32 and 38% of bladder tumor
tissues and urine samples of patients with bladder
cancer, respectively (Figure 4b). Allelic losses in
the three remaining deleted regions could be detec-
ted in less than 15% of tumors (Table 1). It is there-
fore highly unlikely that they contained tumor
suppressor genes frequently involved in the deve-
lopment of bladder cancer. Interestingly, allelic loss
within 13q14 was seen more frequently in super-
ficial bladder tumors than in invasive carcinomas,
but could not be related to histologic grade or
growth pattern (Table 1). More importantly, such
loss did not necessarily correlate with the inactiva-
tion of RB1 gene as documented by immunohisto-
chemical staining of tumor tissues (Figure 4a). In
addition, although statistically nonsignificant, mar-
kers mapping to flanking regions of RB1 exhibited
LOH more often than markers located within RB1. T
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Figure 5 An example of high-resolution whole-organ mapping by genotyping of SNPs and the assembly of LOH distribution patterns in a
single cystectomy specimen. (a) A sequence-based map of a 27-Mb region flanked by markers D13S263 and D13S275 is shown. The
positions of hypervariable markers are shown on the left side of the map. Bars on the right side of the map depict the positions of known
and predicted genes. (b) The genomic map of RB1, ITM2B, and CHC1L with its flanking regions spanning 0.8 Mb is expanded. The
positions of the RB1, ITM2B, and CHC1L exons are shown on the left side of the map. The positions of 79 SNPs and hypervariable DNA
markers are shown on the right side of the map. The arrow in the expanded map indicate the direction of transcription for RB1. (c) The
distribution of clonal allelic losses as they relate to preneoplastic in situ lesions and invasive carcinoma shown as a histologic map at the
bottom is illustrated (map 5). The blocks illustrate the distribution of clonal allelic losses identified by SNPs and RB1.2 as well as RB1.20
markers. The code for the histologic map is identical to the code shown in Figure 1. A clonal plaque-like loss involving a large area of
bladder mucosa for the markers and SNPs within RB1 and its flanking centromeric (Cent) and telomeric (Tel) region is evident. The
predicted size of lost regions estimated by the positions of hypervariable DNA markers and SNP with loss of polymorphism and the
positions of nearest-flanking markers with retention of heterozygosity or SNPs with retention of polymorphism is depicted by the shaded
vertical bars superimposed over the map. (d) An example of retention of an A/C polymorphism in all bladder mucosal samples of the first
informative SNP above ITM2B, which defines the upper centromeric border of the deleted region is shown. (e) An example of clonal loss
of a T/C polymorphism in SNP located within RB1. Note that peripheral blood sample of the same patient shows retention of a T/C
polymorphism in the same SNP. (f) An example of retention of a T/C polymorphism in all mucosal samples of the first informative SNP
located below RB1, which defines the telomeric border of the allelic loss involving RB1 and its proximal–centromeric region. It also
defines a breakpoint between a separate region of allelic loss located telomerically to RB1. (g) The presence of RB1 protein expression
corresponding to NU, LGIN, HGIN, and TCC correlated with the sequencing data, which documented that the wild-type sequence of the
remaining RB1 allele was retained in this case. Positive RB1 nuclear staining was seen in samples corresponding to preneoplastic in situ
lesions (LGIN and HGIN) as well as in TCC. Solid black bars, 50mm.
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This trend was particularly evident when allelic
losses within RB1 and its flanking regions were
tested on voided urine samples of patients with
bladder cancer (Figure 4c). Overall these data
provided evidence that the 13q14 region of chromo-
some 13 is most frequently altered in bladder
neoplasia and confirmed whole-organ histologic
and genetic mapping data supporting the concept
of alternative target genes mapping to flanking
regions of RB1.
Integration of SNP-Based Deletion Map of RB1 with
RB1 Sequencing, Promoter Methylation, and RB1
Protein Expression Status
We next focused our attention on the pattern of RB1
involvement in the development of urothelial
neoplasia by genotyping SNP sites within and
around RB1 in all mucosal samples of cystectomy
specimens. When patterns of allelic losses revealed
by markers mapping within and around RB1 were
integrated with RB1 sequencing data and RB1
protein expression patterns, it became evident that
losses in this region were associated with clonal
expansion but not necessarily with the inactivation
of the remaining RB1 allele (Figure 5a–g). Even in
those cases in which the inactivation of the remain-
ing RB1 allele by a point mutation took place, it was
a later event that accompanied the onset of severe
dysplasia/carcinoma in situ progressing to invasive
carcinoma (Figure 6a–d). None of the cases showed
an abnormal methylation pattern of the CpG island
located upstream of RB1 (Figure 6e). The pattern of
alterations implied that deletions involving approxi-
mately 2 Mb segments of DNA-flanking RB1 were
important for early clonal expansion of preneo-
plastic lesions and that such deletions were not
necessarily associated with the inactivation of the
remaining RB1 allele.
Discussion
Our observations indicate that some of the incipient
events of human bladder neoplasia are associated
with hits that map to flanking regions of a model
tumor suppressor gene, namely RB1. We have
provided evidence that the segment mapping to
13q14, flanked by D13S263 and D13S276, was
involved in approximately 30–40% of bladder
tumors and was typically lost in the early intrauro-
thelial phases of bladder neoplasia. Moreover, the
loss preceded the development of microscopically
recognizable precursor lesions and did not involve
loss of RB1 function. The inactivation of RB1
occurred later, at the time severe dysplasia/carci-
noma in situ developed. Such a pattern of altera-
tions in 13q14 implied that genes distinct from RB1
but mapping to its flanking regions were involved in
the expansion of the initial neoplastic clone.
Tissue culture observations show, in contrast to
the findings in non-human cells, that cooperating
oncogenes and tumor suppressor genes alone are not
sufficient to transform normal human cells into
malignant cells.28–30 The successful creation of
human tumor cells in vitro typically requires the
use of chemical and physical agents or an entire
viral genome to achieve immortalization, a prere-
quisite for subsequent transforming effects of co-
operating oncogenes.31–34 More recently, human
epithelial and fibroblast cells were transformed in
vitro by ectopic expression of telomerase catalytic
subunit (hTERT) in combination with two onco-
genes (the Simian virus 40 large-T oncoprotein and
an oncogenic allele of H-ras).35,36
Figure 6 Integration of deletion patterns identified in the 13q14 region with RB1 sequencing data and RB1 protein expression patterns.
(a) The deleted regions associated with early clonal expansion identified by whole-organ histologic and genetic mapping with 79 SNPs
and hypervariable DNA markers in six cystectomy specimens are related to the status of RB1 sequence (RB1(S)) and RB1 protein
expression revealed by immunohistochemistry (RB1(IH)). The results of RB1 sequencing and protein expression are tabulated below the
deletion maps of individual cystectomy specimen. The results of methylation status of RB1 promoter region are summarized in (e). The
blue bars in each whole-organ histologic depict the deleted regions identified by genotyping of SNPs and genetic map (WHOM)
numbered 1–6. The red bars designate allelic losses identified by hypervariable DNA markers. The positions and distances of deleted
regions are defined as described in Figure 5c. Maps 7 and 8 in which no allelic loss within 13q14 region was identified are not shown.
Note that in map 2, losses within RB1 and its flanking telomeric region were identified by genotyping of SNPs only. (b) An example of
clonal allelic loss of an A/C polymorphism in SNP located below RB1 within its flanking telomeric region (map 5). Note retention of A/C
polymorphism in the peripheral blood sample (PB DNA) of the same patient. (c) The immunohistochemical pattern of RB1 protein
expression in representative mucosal samples of map 2 (c). Note the absence of RB1 protein expression in HGIN and TCC corresponding
to an area containing a mutant RB1 allele. This pattern of allelic losses with and without inactivation of the remaining RB1 allele
provides evidence that other genes mapping to the flanking regions rather than RB1 itself are involved in the initial in situ expansion of a
preneoplastic clone (also see Figure 5). (d) The distribution of clonal allelic losses involving RB1 and its flanking telomeric (Tel) region in
map 2. Note that the area corresponding to the presence of mutant RB1 and the absence of RB1 protein expression is restricted to TCC and
to adjacent areas of HGIN. In contrast, an allelic loss involving the region telomeric to RB1 is associated with clonal in situ expansion
involving almost the entire bladder mucosa. (e) Summary of methylation-specific PCR in cystectomy specimens 1–8. P1, positive
control—normal lymphocyte DNA (for unmethylated form) or normal lymphocyte DNA treated with SssI methyl transferase (for
methylated form); P2, positive control—RB1 methylation of known retinoblastoma tumor; N, negative control is water blank or PCR
cocktail without template. U, unmethylated form; and M, methylated form. p16 was run as a control for DNA integrity. The sizes of
amplified segments are shown within parentheses. Note the absence of methylation-specific product for RB1 in tumor samples of maps
1–8, indicating that none of the cases included in the study contained RB1 with methylated promoter. Overall, the data summarized in
this figure indicate that the genes involved in clonal expansion of human bladder preneoplasia are located within approximately 2 Mb
around RB1.
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Widespread clonal in situ proliferations as inci-
pient events of human neoplasia were documented
in vivo for gastrointestinal, esophageal, and breast
carcinogenesis.1–3 Prior studies showing the dis-
cordance between allelic loss in 13q14 and the
inactivation of RB1 are in keeping with our results,
and have also implicated other genes mapping to
this region in the development of several human
malignancies.37–43 The presence of clonal allelic loss
involving 13q14 and other regions containing tumor
suppressor genes explains the efficiency of detec-
tion of bladder neoplasia by testing microsatellite
markers mapping to these regions in voided urine
samples.44–46 Such markers are effective not only
in detecting clinically evident bladder cancer but
are also efficient tools to identify occult bladder
neoplasia and predict recurrence.47
Whole-organ histologic maps of human bladders
obtained by cystectomy, generated more than two
decades ago, provided the foundation for our
current pathologic concepts of urothelial neoplasia.
They postulated that bladder cancer develops via
two distinct but somewhat overlapping pathways,
papillary and nonpapillary.13,14 More recent mole-
cular studies confirmed these initial clinicopatho-
logic observations and showed that these two basic
forms of bladder cancer are associated with distinct
molecular alterations.5,48,49 The involvement of
major tumor suppressor genes such as p53 and
RB1 as well as their upstream and downstream
regulatory partners is typical for the high-grade
nonpapillary form of bladder cancer characterized
by aggressive behavior and a high propensity for
distant metastasis.5
Our current mapping studies showed that human
urothelial neoplasia starts as a widespread clonal
proliferation of preneoplastic urothelial cells with
the establishment of a dominant clone. In this
scenario, the involvement of a key tumor suppressor
gene is secondary and signifies the onset of a fully
transformed phenotype with microscopic features
of severe dysplasia/carcinoma in situ capable of
progressing to invasive cancer. The possibility
that the RB1 haplotype may have an effect on
the development of incipient preneoplastic condi-
tions cannot be completely ruled out by the ana-
lysis of losses in the 13q14 region. However, the
clinical data implicate that the RB1 haplotype
has no effect on cell biology as documented by
the presence of familial syndromes, which carry a
mutant inactive allele of RB1 in normally develop-
ing somatic cells.50,51 A similar alteration pattern
was previously reported by us for the p53-contain-
ing region and provides additional support for the
existence of alternative candidate genes mapping,
in general, near major tumor suppressors that may
be critical for the initial expansion of preneoplastic
clones.6
The presence of clonal discontinuous deletions
within the RB1 region implies that such changes
occurred during an early phase of in situ neoplasia.
The development of such complex deletions in a
form of one synchronous hit is very unlikely. The
more likely scenario is that they evolved as
sequential events. The presence of discontinuous
deletions in the region also implies that not all of
them were functionally valid and some of them were
dragged through clonal expansion as passenger
changes. Overall, such findings suggest that the
early preclonal phase of tumor development is
associated with the high degree of genetic instability
followed by a more stable phase of clonal in situ
expansion. The mapping evidence suggesting the
presence of alternative positional candidate genes
near RB1 involved in the development of in situ
neoplasia is associative, but the clonality of the hits
forming large plaques in bladder mucosa and
consistency of such findings suggest functional
relevance. The size of the 13q14 segment involved
by clonal allelic losses indicate that the alternative
candidate genes should be present within approxi-
mately 2 Mb around RB1. The pattern of involve-
ment of microsatellite markers mapping to the
flanking regions of RB1 tested on multiple tumor
and voided urine samples, which did not reach the
statistical significance, suggests that alternative
positional candidate genes may, in fact, be located
in close proximity to RB1.
The precise identification of alternative positional
candidate genes near RB1 that may drive the initial
clonal expansion of bladder neoplasia will require
high-throughput mapping of the 13q14 region. We
estimate that for such whole-organ mapping studies,
we will need allelotyping of 500–1000 SNPs in at
least five informative cystectomy specimens. We
predict that 10 000–15 000 tests will have to be
performed to construct a precise map of sequential
hits near RB1. Such labor intense studies are feasible
with the assistance of robotic instruments and are
currently being conducted in our laboratory.
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